https://www.nasdaq.com/press-release/altimmune-to-present-pemvidutide-clinical-data-at-upcoming-nash-tag-conference
https://www.nasdaq.com/press-release/altimmune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-12-13
https://www.nasdaq.com/press-release/altimmune-appoints-richard-eisenstadt-as-chief-financial-officer-2021-12-13
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-investor-and-scientific-conferences-2021-11-22
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-investor-conferences-2021-11-10
https://www.nasdaq.com/press-release/altimmune-announces-third-quarter-2021-financial-results-and-provides-a-corporate
https://www.nasdaq.com/press-release/altimmune-to-announce-third-quarter-2021-financial-results-on-november-10-2021-2021
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-h.c.-wainwright-investor-conferences-october-12-13
https://www.nasdaq.com/press-release/altimmune-announces-initiation-of-12-week-phase-1b-trial-of-pemvidutide-in-subjects
https://www.nasdaq.com/press-release/altimmune-to-host-key-opinion-leader-call-with-dr.-stephen-harrison-on-pemvidutide
https://www.nasdaq.com/press-release/altimmune-announces-positive-results-from-12-week-phase-1-clinical-trial-of-alt-801
https://www.nasdaq.com/press-release/altimmune-to-announce-12-week-data-from-alt-801-phase-1-trial-on-september-28-2021
https://www.nasdaq.com/press-release/altimmune-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment-conference
https://www.nasdaq.com/press-release/altimmune-announces-second-quarter-2021-financial-results-and-provides-a-corporate
https://www.nasdaq.com/press-release/altimmune-to-announce-second-quarter-2021-financial-results-on-august-11-2021-2021-08
https://www.nasdaq.com/press-release/altimmune-announces-update-on-adcovidtm-phase-1-clinical-trial-2021-06-29
https://www.nasdaq.com/press-release/altimmune-announces-positive-interim-data-from-alt-801-phase-1-trial-in-overweight
https://www.nasdaq.com/press-release/altimmune-to-present-at-the-2021-jefferies-virtual-healthcare-conference-2021-05-27
https://www.nasdaq.com/press-release/altimmune-demonstrates-strong-neutralization-of-south-african-variant-in-preclinical
https://www.nasdaq.com/press-release/altimmune-announces-first-quarter-2021-financial-results-and-provides-a-corporate
https://www.nasdaq.com/press-release/altimmune-to-announce-first-quarter-2021-financial-results-on-may-17-2021-2021-05-11
https://www.nasdaq.com/press-release/altimmune-announces-new-preclinical-data-for-adcovidtm-demonstrating-sterilizing
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-scientific-conferences-2021-04-29
https://www.nasdaq.com/press-release/altimmune-reports-data-from-its-phase-1b-clinical-trial-of-nasoshieldtm-2021-04-01
https://www.nasdaq.com/press-release/altimmune-partners-with-summit-biosciences-to-produce-a-multidose-nasal-spray
https://www.nasdaq.com/press-release/adcovidtm-altimmunes-single-dose-intranasal-covid-19-vaccine-candidate-prevents-sars
https://www.nasdaq.com/press-release/altimmune-expands-adcovidtm-manufacturing-collaboration-with-lonza-2021-03-12
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-conferences-2021-03-08
https://www.nasdaq.com/press-release/altimmune-commences-enrollment-in-phase-1-clinical-trial-of-adcovidtm-a-needle-free
https://www.nasdaq.com/press-release/altimmune-announces-financial-results-for-the-year-ended-december-31-2020-and
https://www.nasdaq.com/press-release/altimmune-to-announce-year-end-2020-financial-results-on-february-25-2021-2021-02-22
https://www.nasdaq.com/press-release/altimmune-announces-fda-clearance-of-adcovidtm-ind-application-2021-02-17
https://www.nasdaq.com/press-release/altimmune-begins-multinational-phase-2-clinical-trial-of-heptcelltm-a-novel
https://www.nasdaq.com/press-release/altimmune-provides-an-update-on-its-investigational-new-drug-application-for-a-phase
https://www.nasdaq.com/press-release/altimmune-to-present-at-the-4th-annual-nash-summit-2020-digital-conference-2020-12-11
https://www.nasdaq.com/press-release/altimmune-commences-dosing-in-phase-1-clinical-trial-of-alt-801-a-long-acting-glp-1
https://www.nasdaq.com/press-release/altimmune-announces-submission-of-investigational-new-drug-application-for-adcovidtm
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-virtual-investor-conferences-2020-11-16
https://www.nasdaq.com/press-release/altimmune-adds-lonza-as-a-manufacturing-partner-for-supply-of-adcovidtm-its-single
https://www.nasdaq.com/press-release/altimmune-announces-third-quarter-2020-financial-results-and-provides-a-business
https://www.nasdaq.com/press-release/altimmune-to-announce-third-quarter-2020-financial-results-on-november-10-2020-11-03
https://www.nasdaq.com/press-release/altimmune-to-present-at-two-upcoming-virtual-investor-conferences-2020-10-15
https://www.nasdaq.com/press-release/altimmune-and-uab-announce-publication-of-compelling-pre-clinical-data-for-adcovidtm
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-investor-conferences-2020-09-30
https://www.nasdaq.com/press-release/altimmune-presents-highlights-of-intranasal-covid-19-vaccine-and-therapeutic-programs
https://www.nasdaq.com/press-release/altimmune-announces-successful-completion-of-multiple-dose-toxicity-and-toxicokinetic
https://www.nasdaq.com/press-release/altimmune-announces-data-presentation-on-alt-801-its-balanced-and-long-acting-glp-1
https://www.nasdaq.com/press-release/altimmune-and-the-university-of-alabama-at-birmingham-announce-potent-respiratory
https://www.nasdaq.com/press-release/altimmune-announces-second-quarter-2020-financial-results-and-provides-a-business
https://www.nasdaq.com/press-release/altimmune-completes-enrollment-in-phase-1b-clinical-trial-of-nasoshieldtm-a-single
https://www.nasdaq.com/press-release/altimmune-to-announce-second-quarter-2020-financial-results-on-august-12-2020-08-05
https://www.nasdaq.com/press-release/altimmune-announces-manufacturing-agreement-with-vigene-biosciences-for-adcovidtm-its
https://www.nasdaq.com/press-release/altimmune-announces-closing-of-%24132-million-public-offering-of-common-stock-and-pre
https://www.nasdaq.com/press-release/altimmune-announces-pricing-of-a-public-offering-of-%24115-million-of-common-stock-and
https://www.nasdaq.com/press-release/altimmune-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants
https://www.nasdaq.com/press-release/altimmune-and-the-university-of-alabama-at-birmingham-uab-announce-positive
https://www.nasdaq.com/press-release/altimmune-signs-teaming-agreement-with-dynport-vaccine-company-on-u.s.-government
https://www.nasdaq.com/press-release/altimmune-announces-dosing-of-first-patient-in-phase-1b-clinical-trial-of
https://www.nasdaq.com/press-release/altimmune-receives-award-from-u.s.-department-of-defense-to-fund-phase-1-2-clinical
https://www.nasdaq.com/press-release/altimmune-announces-ind-clearance-for-a-phase-2-trial-of-heptcelltm-immunotherapeutic
https://www.nasdaq.com/press-release/altimmune-launches-clinical-trial-of-t-covidtm-an-investigational-intranasal-immune
https://www.nasdaq.com/press-release/altimmune-announces-first-quarter-2020-financial-results-and-provides-a-business
https://www.nasdaq.com/press-release/altimmune-appoints-former-pfizer-and-gsk-executive-diane-jorkasky-m.d.-to-its-board
https://www.nasdaq.com/press-release/altimmune-to-announce-first-quarter-2020-financial-results-on-may-14-2020-05-08
https://www.nasdaq.com/press-release/altimmune-and-the-university-of-alabama-at-birmingham-to-collaborate-on-development
https://www.nasdaq.com/press-release/altimmune-announces-financial-results-for-the-year-ended-december-31-2019-and
https://www.nasdaq.com/press-release/altimmune-to-announce-year-end-2019-financial-results-on-march-27-2020-03-25
https://www.nasdaq.com/press-release/altimmune-completes-first-development-milestone-toward-a-single-dose-intranasal-covid
https://www.nasdaq.com/press-release/altimmune-to-present-at-the-cowen-40th-annual-health-care-conference-2020-02-19
https://www.nasdaq.com/press-release/altimmune-to-present-at-upcoming-investor-and-scientific-conferences-2020-02-04
https://www.nasdaq.com/press-release/altimmune-announces-positive-results-for-alt-702-in-preclinical-model-of-colorectal
https://www.nasdaq.com/press-release/altimmune-to-present-at-the-2020-nash-tag-conference-2020-01-07
https://www.nasdaq.com/press-release/altimmune-to-host-key-opinion-leader-call-on-alt-801-for-the-treatment-of-nash-2019
https://www.nasdaq.com/press-release/altimmune-announces-third-quarter-2019-financial-results-and-provides-a-business
https://www.nasdaq.com/press-release/altimmune-to-announce-third-quarter-2019-financial-results-on-november-14-2019-11-06
https://www.nasdaq.com/press-release/altimmune-to-participate-in-upcoming-investor-conferences-2019-10-10
https://www.nasdaq.com/press-release/altimmune-appoints-m.-scott-harris-m.d.-as-chief-medical-officer-2019-09-10
https://www.nasdaq.com/press-release/altran-technologies-aricent-become-altran-2019-04-21
https://www.nasdaq.com/press-release/altimmune-announces-financial-results-year-ended-december-31-2018-and-provides
https://www.nasdaq.com/press-release/altimmune-announce-year-end-2018-financial-results-april-2-2019-04-21
